Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

CymaBay Therapeutics

Thumbnail
November 03, 2020

AASLD 2020 – Nash updates from Novo and Inventiva in focus

At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.

Thumbnail
August 03, 2020

The Cymabay recovery continues

Encouraging cholangitis data follows the lifting of a clinical hold on Cymabay’s seladelpar, signalling a way forward for a project that looked finished.

Article image
Vantage logo
June 16, 2020

Inventiva gets a surprise hit in Nash

Inventiva’s mid-stage win has revived hopes for PPAR agonists in the liver disease, although safety questions remain.

Article image
Vantage logo
May 12, 2020

Genfit’s predictable liver disease failure sets up a cirrhosis pivot

Five years after failing phase II in Nash, elafibranor fails phase III in Nash; a focus on liver cirrhosis beckons.

Article image
Vantage logo
March 06, 2020

Upcoming events – Fibroid data for Obseva, as Inventiva turns to Nash

Phase III data for Obseva's uterine fibroid project linzagolix need to prove its safety, while Inventiva tests its pan-PPAR agonist lanifibranor in Nash.

Article image
Vantage logo
February 21, 2020

Genfit's latest delay could see a last-minute endpoint change

Article image
Vantage logo
December 18, 2019

As Nash shifts again, the focus remains on Genfit’s big readout

Genfit investors, who early next year will see the Resolve-It study yield data, digest further developments in the Nash space.

Article image
Vantage logo
November 26, 2019

Cymabay is out, but for Genfit the band plays on

A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?

Article image
Vantage logo
September 19, 2019

Genfit’s liver disease Hail Mary approaches

Genfit's quiet delay means it will be five years since a Nash failure before investors find out whether pressing on into phase III was worth it.

Article image
Vantage logo
June 27, 2019

As Genfit deals and Conatus folds, Nash plays on

A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of…

Article image
Vantage logo
June 11, 2019

Cymabay can’t buck the Nash disappointment trend

As placebo outperforms Cymabay’s seladelpar attention turns to the pivotal trial of Genfit’s elafibranor.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
March 22, 2021

AACR 2021 preview – the early themes emerge

Vantage logo
March 24, 2021

Big pharma’s key catalysts in the second quarter

Vantage logo
March 03, 2021

A busy year ahead for Parkinson’s disease

Vantage logo
March 23, 2021

Frequency refuses to hear the death knell

Vantage logo
February 18, 2021

The reckoning begins for biotech-focused Spacs

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.